Clinical Trial

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 5, 2022 (before its estimated August 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide scientific basis for the formulation of the best comprehensive treatment plan in the future.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-01.
Trial Details
NCT Number NCT05484583
Lead Sponsor Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Conditions Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy
Enrollment 58 participants
Start Date 2022-08-01
Primary Completion 2024-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2022-08-05